Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Thomas Grombacher

Showing results (1-10 of 9) with videos related to

Pageof 1
Sort By:
Journal of Chemical Information and Modeling|October 16, 2010
Analyzing the topology of active sites: on the prediction of pockets and subpocketsAndrea Volkamer, Axel Griewel, Thomas Grombacher, et al.
Journal of Chemical Information and Modeling|December 14, 2011
Combining global and local measures for structure-based druggability predictionsAndrea Volkamer, Daniel Kuhn, Thomas Grombacher, et al.
Pharmacogenomics|March 21, 2024
Implementation of whole-exome sequencing for pharmacogenomics profiling and exploring its potential clinical utilitiesDanyi Wang, Jayaprakasam Bolleddula, Anna Coenen-Stass, et al.
Nature Communications|December 14, 2023
Mapping combinatorial drug effects to DNA damage response kinase inhibitorsHanrui Zhang, Julian Kreis, Sven-Eric Schelhorn, et al.
Neoplasia (New York, N.Y.)|September 28, 2021
RosettaSX: Reliable gene expression signature scoring of cancer models and patientsJulian Kreis, Boro Nedić, Johanna Mazur, et al.
Molecular Cancer Therapeutics|April 11, 2022
A New Class of Selective ATM Inhibitors as Combination Partners of DNA Double-Strand Break Inducing Cancer TherapiesAstrid Zimmermann, Frank T Zenke, Li-Ya Chiu, et al.
Molecular Cancer Therapeutics|March 30, 2020
Pharmacologic Inhibitor of DNA-PK, M3814, Potentiates Radiotherapy and Regresses Human Tumors in Mouse ModelsFrank T Zenke, Astrid Zimmermann, Christian Sirrenberg, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 26, 2024
First-in-Human Study of the Ataxia Telangiectasia and Rad3-Related (ATR) Inhibitor Tuvusertib (M1774) as Monotherapy in Patients with Solid TumorsTimothy A Yap, Anthony W Tolcher, Ruth Plummer, et al.
NPJ Breast Cancer|April 8, 2022
Phase 1b study of berzosertib and cisplatin in patients with advanced triple-negative breast cancerMelinda L Telli, Sara M Tolaney, Geoffrey I Shapiro, et al.
Pageof 1

Showing results (1-10 of 9) with videos related to

Sort By:
Pageof 1
Journal of Chemical Information and Modeling|October 16, 2010
Analyzing the topology of active sites: on the prediction of pockets and subpocketsAndrea Volkamer, Axel Griewel, Thomas Grombacher, et al.
Journal of Chemical Information and Modeling|December 14, 2011
Combining global and local measures for structure-based druggability predictionsAndrea Volkamer, Daniel Kuhn, Thomas Grombacher, et al.
Pharmacogenomics|March 21, 2024
Implementation of whole-exome sequencing for pharmacogenomics profiling and exploring its potential clinical utilitiesDanyi Wang, Jayaprakasam Bolleddula, Anna Coenen-Stass, et al.
Nature Communications|December 14, 2023
Mapping combinatorial drug effects to DNA damage response kinase inhibitorsHanrui Zhang, Julian Kreis, Sven-Eric Schelhorn, et al.
Neoplasia (New York, N.Y.)|September 28, 2021
RosettaSX: Reliable gene expression signature scoring of cancer models and patientsJulian Kreis, Boro Nedić, Johanna Mazur, et al.
Molecular Cancer Therapeutics|April 11, 2022
A New Class of Selective ATM Inhibitors as Combination Partners of DNA Double-Strand Break Inducing Cancer TherapiesAstrid Zimmermann, Frank T Zenke, Li-Ya Chiu, et al.
Molecular Cancer Therapeutics|March 30, 2020
Pharmacologic Inhibitor of DNA-PK, M3814, Potentiates Radiotherapy and Regresses Human Tumors in Mouse ModelsFrank T Zenke, Astrid Zimmermann, Christian Sirrenberg, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 26, 2024
First-in-Human Study of the Ataxia Telangiectasia and Rad3-Related (ATR) Inhibitor Tuvusertib (M1774) as Monotherapy in Patients with Solid TumorsTimothy A Yap, Anthony W Tolcher, Ruth Plummer, et al.
NPJ Breast Cancer|April 8, 2022
Phase 1b study of berzosertib and cisplatin in patients with advanced triple-negative breast cancerMelinda L Telli, Sara M Tolaney, Geoffrey I Shapiro, et al.
Pageof 1